Eventide Asset Management’s enGene Therapeutics ENGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$6.81M Buy
+3,406,023
New +$6.3M 0.1% 172
2026
Q1
– Sell
-950,000
Closed -$8.58M – 286
2025
Q4
$8.58M Buy
+950,000
New +$7.61M 0.13% 149

Other funds holding ENGN

Eventide Asset Management's ENGN Position: Q3 2026 in Review

Eventide Asset Management opened a new position in enGene Therapeutics (ENGN) in Q3 2026: 3,406,023 shares worth $6.81M. The stake represents 0.1% of the portfolio and ranks #172 among its holdings. This is a return to the name: Eventide Asset Management previously reported a position in ENGN as recently as Q4 2025.

Eventide Asset Management first reported a position in ENGN in Q4 2025 and has held it in 2 quarters since. The position peaked at $8.58M in Q4 2025. 60 funds tracked by Wall St. Rank hold ENGN as of Q3 2026.

  • Eventide Asset Management held 3,406,023 shares of enGene Therapeutics worth $6.81M as of Q3 2026.
  • enGene Therapeutics was a new Eventide Asset Management position in Q3 2026.
  • enGene Therapeutics made up 0.1% of Eventide Asset Management's portfolio in Q3 2026, its #172 holding.
  • Eventide Asset Management first reported a position in enGene Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Eventide Asset Management's enGene Therapeutics position peaked at $8.58M in Q4 2025.
  • 60 funds tracked by Wall St. Rank held enGene Therapeutics as of Q3 2026.

Based on Eventide Asset Management's 13F filing for Q3 2026, filed 13 Nov 2026.